Xarelto Is The Pharma Watchword In Bayer's 3Q Update

 
• By Lucie Ellis-Taitt
  
blood clot
Bayer targets 2017 regulatory filings for Xarelto in coronary artery and peripheral arterial disease
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business